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ABSTRACT
MYCN is a master regulator controlling many pro-
cesses necessary for tumor cell survival. Here, we
unravel a microRNA network that causes tumor sup-
pressive effects in MYCN-amplified neuroblastoma
cells. In profiling studies, histone deacetylase
(HDAC) inhibitor treatment most strongly induced
miR-183. Enforced miR-183 expression triggered
apoptosis, and inhibited anchorage-independent
colony formation in vitro and xenograft growth in
mice. Furthermore, the mechanism of miR-183 in-
duction was found to contribute to the cell death
phenotype induced by HDAC inhibitors. Experi-
ments to identify the HDAC(s) involved in miR-183
transcriptional regulation showed that HDAC2 de-
pletion induced miR-183. HDAC2 overexpression
reduced miR-183 levels and counteracted the induc-
tion caused by HDAC2 depletion or HDAC inhibitor
treatment. MYCN was found to recruit HDAC2 in the
same complexes to the miR-183 promoter, and
HDAC2 depletion enhanced promoter-associated
histone H4 pan-acetylation, suggesting epigenetic
changes preceded transcriptional activation. These
data reveal miR-183 tumor suppressive properties in
neuroblastoma that are jointly repressed by MYCN
and HDAC2, and suggest a novel way to bypass
MYCN function.
INTRODUCTION
Neuroblastoma is a tumor originating from neuroecto-
dermal progenitor cells, and is the most frequent
extracranial solid tumor in childhood (1). A characteristic
feature of neuroblastoma is its heterogeneity, ranging
from spontaneous regression to fatal outcome (2).
Amplification of the MYCN proto-oncogene is detected
in 20–30% of neuroblastomas, and predicts a poor
survival (3). MYCN regulates the transcriptional activa-
tion and repression of numerous target genes and
microRNAs (miRNAs) by recruiting co-factors or co-re-
pressors to create an open or repressed chromatin state,
respectively, (4).
MicroRNAs are small non-protein-coding RNA mol-
ecules encoded in the genome that are important for
diverse cellular processes, including development, differ-
entiation, cell cycle regulation and apoptosis (5).
MicroRNAs mainly control gene expression by regulating
mRNA translation or stability (6). Because of these regu-
latory functions, miRNAs can act as oncogenes or tumor
suppressors, and aberrant miRNA expression profiles are
involved in the initiation and progression of cancer (7,8).
Differential miRNA expression profiles were identified in
neuroblastomas (9,10), and a miRNA-based classifier has
been shown to predict outcome of neuroblastoma patients
(11). A genome-wide study for MYCN binding sites in
promoters revealed that MYCN regulates the expression
of oncogenic and tumor suppressive miRNAs (12). Hence,
elucidating mechanisms regulating the expression of
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individual miRNAs and the mechanisms they control is
important to understand neuroblastoma biology. Previous
studies have reported that histone deacetylase inhibitors
(HDACi) influence miRNA expression levels in cancer
cells (13).
Histone deacetylases (HDACs) are enzymes that remove
acetyl groups from lysine residues of histones and non-
histone proteins (14). The HDAC family consists of the
Zn2+-dependent classical members of class I (HDAC1, 2,
3, 8), class IIa (HDAC4, 5, 7, 9), class IIb (HDAC6, 10)
and class IV (HDAC11) and the NAD+-dependent
members of class III (SIRT1-7) (14,15). HDACs are
involved in regulating gene expression via their enzymatic
function or as structural components of multiprotein
complexes. Aberrant HDAC recruitment and expression
and deregulated histone H4 acetylation has been described
for tumor cells (16–18). HDACi exert anti-tumoral effects
against diverse tumor entities, including neuroblastoma
(16,19,20). Nevertheless, the underlying molecular mech-
anisms are largely unknown.
Here we present miR-183 as a tumor suppressor in
highly malignant MYCN-amplified neuroblastoma cells
and unravel the mechanism of regulation behind this func-
tionality. The repression of miR-183 by MYCN and
HDAC2 indicates HDAC inhibition as a potential novel
strategy to activate miR-183 tumor suppressive functions.
MATERIALS AND METHODS
Cell culture
The BE(2)-C, Kelly, SH-SY5Y, SH-EP and IMR-32
neuroblastoma cell lines were cultured in RPMI 1640 or
DMEM with 10% fetal calf serum (FCS; Sigma-Aldrich,
Munich, Germany) and 1% non-essential amino acids
(NEAA; Invitrogen, Darmstadt, Germany) at 37C, 5%
CO2. MYCN-amplified NB8 tumor spheres were estab-
lished from a short-term culture (NB-S-124) of highly
infiltrated bone marrow aspirate kindly provided by co-
author F.W., and were grown in Neurobasal A
(Invitrogen) with 2% B27 (Invitrogen), 20 ng/ml bFGF
(Promocell, Heidelberg, Germany) and 20 ng/ml EGF
(Promocell) at 37C, 5% CO2. BE(2)-C cells stably trans-
fected with an inducible miR-183 or miR negative control
expression system were cultured in DMEM supplemented
with 10% FCS, 1% NEAA, 1.5mg/ml G418 (Calbiochem,
Darmstadt, Germany) and 7.5 mg/ml blasticidin (Sigma-
Aldrich). To induce miR expression, cells were treated
with 100 ng/ml doxycycline (Sigma-Aldrich). IMR-32
cells stably transfected with a tetracycline-inducible
MYCN shRNA expression system (IMR32-6TR-
MYCNsh) were cultured in DMEM with 10% FCS and
1% NEAA supplemented with 250 mg/ml Zeocin
(Invitrogen) and 5 mg/ml blasticidin. Cells were treated
with 1 mg/ml tetracycline (AppliChem, Darmstadt,
Germany) to induce shMYCN expression. All cell lines
were regularly monitored for mycoplasma, Acholeplasma
laidlawii and squirrel monkey retrovirus (SMRV) infec-
tions by high-throughput multiplex cell contamination
testing (McCT) (21).
HDACi
Stock solutions of Panobinostat (1mM; Selleck Chemi-
cals, Houston, TX, USA), PCI-24781 (10mM; Pharmacy-
clics, Sunnyvale, CA, USA), Vorinostat (1mM; Chemos,
Regenstauf, Germany), Entinostat (1mM; Calbiochem),
Tubacin (100mM; provided by Christian Hildmann
(Ilmenau, Germany)), Compound 2 (250mM; provided
by Scott M. Ulrich (Ithaca, NY, USA)) and Trichostatin
A (100 mM; Calbiochem) were prepared in dimethyl sulf-
oxide (DMSO). HC-toxin (0.1mM; Sigma-Aldrich) was
dissolved in methanol.
Pre-miR miRNA Precursor miRNAs, Anti-miR miRNA
Inhibitors, siRNAs, plasmid DNAs and transfection
Pre-miR miRNA Precursor for hsa-miR-183 (Applied
Biosystems) was transfected at a concentration of 30 nM
using HiPerFect (Qiagen) according to the manufacturer’s
instructions. Pre-miR miRNA Precursor Molecules
Negative Control #1 and #2 were used as controls. Anti-
miR miRNA Inhibitor for hsa-miR-183 and the control
Anti-miR miRNA Inhibitors Negative Control #1
(Applied Biosystems) were transfected at a concentration
of 200 nM using HiPerFect. Small interfering RNAs
(siRNAs) or non-silencing negative control siRNAs
(AllStars Negative Control siRNA, Qiagen; siGenome
RISC-free control siRNA, Thermo Fisher Scientific,
Schwerte, Germany) were transfected using HiPerFect in
a concentration of 25 nM. All siRNAs used are
summarized in Supplementary Table S4. For plasmid
transfection, 1–4 mg DNA were used together with
Lipofectamine (Invitrogen). The expression plasmid con-
taining the full-length human HDAC2 cDNA sequence
with a His-tag (HS_HDAC2_IM_2 QIAgenes Expression
Kit Insect/Mammalia) and the corresponding empty
vector pQE-TriSystem-6 were obtained by Qiagen. For
rescue experiments, combining HDAC2 knockdown and
enforced HDAC2 expression, the HDAC2 siRNA#2
(Qiagen) was used. The HDAC2 expression plasmid
contains an optimized human protein-coding sequence.
Silent mutations were introduced in the sequence to
optimize codon usage and mRNA stability, while the
amino acid sequence of the HDAC2 protein remained un-
altered (QIAgenes Insect/Mammalia Handbook, July
2009). Plasmid sequence and HDAC2 siRNA#2 target
sequence differ in 5 nt, and the plasmid sequence is there-
fore, other than the endogenous HDAC2 mRNA
sequence, not effectively targeted by this siRNA.
RNA isolation and quantitative RT-PCR
Total RNA was isolated from cell cultures or snap-frozen
tissue using the miRNeasy Mini Kit (Qiagen, Hilden,
Germany). M-MLV reverse transcriptase (Invitrogen)
and random hexamer primers (Invitrogen) were used to
transcribe cDNAs. Gene expression was measured by
qRT-PCR using SYBR Green Dye (Eurogentec,
Cologne, Germany) on an ABI Prism 7700 thermal
cycler (Perkin-Elmer Applied Biosystems, Weiterstadt,
Germany) as previously described (19), and normalized
to the averaged SDHA and HPRT1 expression, genes
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which are consistently expressed in stage 4 and 4S neuro-
blastomas (22). All primers used are summarized in the
Supplementary Material (Supplementary Table S2).
Quantification of mature miRNAs was performed using
TaqMan MicroRNA Assays (Applied Biosystems, Darm-
stadt, Germany). Detection of mature miR-183 was con-
firmed by sequencing. A Custom TaqMan Small RNA
Assay (Applied Biosystems) was used for detection of
miR negative control expression (miR-neg ctrl; sequence:
50-AAAUGUACUGCGCGUGGAGAC-30). RNU6B
and RNU48 were used for normalization. Relative miR-
183 expression in xenografts was calculated using a
standard curve. Relative expression levels in different
cell lines were calculated using the mean expression of
all samples as a calibrator. All expression analyses were
performed using Applied Biosystems Prism software and
the CT method.
Western blot analysis
Cells were lysed for western blotting in buffer containing
20mM Tris-HCl, 7M urea, 0.01% Triton X-100, 100mM
dithiothreitol (DTT), 40mM MgCl2 and Complete
protease inhibitor cocktail (Roche, Mannheim,
Germany). For the detection of histone H3 acetylation
levels, cells were lysed in SDS lysis buffer (62.5mM Tris-
HCl, 2% SDS, 10% (v/v) glycerol, 1mM DTT and
Complete protease inhibitor cocktail). The following
antibodies were used: anti-HDAC2 (3F3, sc-81599,
Santa Cruz, Heidelberg, Germany), anti-MYCN
(B8.4.B, sc-53993, Santa Cruz), anti-Penta-His antibody
(Qiagen), anti-Ezrin (3C12, sc-58758, Santa Cruz), anti-
acetyl-Histone H3 (Lys14) (06-911, Millipore, Schwal-
bach, Germany), anti-Histone H3 (#9715, Cell Signaling
Technology, Danvers, MA, USA), anti-GAPDH (clone
6C5, Millipore) and anti-ß-actin (clone AC-15, Sigma-
Aldrich).
ChIP, Re-ChIP, ChIP-Seq and ChIP-on-chip
Cells were lysed for ChIP in buffer containing 50mM Tris-
HCl, pH 8.1, 1% SDS, 10mM EDTA and Complete
protease inhibitor cocktail (Roche), then sonified to
obtain 200–1000 bp DNA fragments. ChIP was performed
according to the ChIP Assay Kit (Millipore) protocol. The
following antibodies were used: anti-acetyl-Histone H4,
anti-MYCN (B8.4.B, sc-53993, Santa Cruz), anti-
HDAC2 (3F3, sc-81599, Santa Cruz), anti-HDAC1
(ab7028, Abcam, Cambridge, UK), normal mouse IgG
(sc-2025, Santa Cruz) and normal rabbit IgG (sc-2027,
Santa Cruz). Primers for specific qRT-PCR amplification
of the miR-183 promoter region were: forward: 50-CGTA
GGGCCACTGGACGA-30, reverse: 50-TTGTCCCCATT
CCAGCCCTG-30. For Re-ChIP analysis, chromatin
precipitated by the first ChIP round was eluted with
10mM DTT in TE buffer for 30min at 37C. Eluates
were diluted 1:20 in ChIP dilution buffer (ChIP Assay
Kit, Millipore), then used in second round of ChIP. For
ChIP-Seq, ChIP samples were prepared and run on
a Genome Analyzer II (Illumina) according to the
manufacturer’s guidelines. Read data were processed in
a Perl-based analysis pipeline using the following
packages: Bowtie for read mapping to the human
GRCh37 assembly (reference genome), SAMtools and
Picard for sequence manipulation, and MACS for peak
calling (23–25). R scripting was used to assess read
quality. Results were visualized with the UCSC genome
browser (GRCh37/hg19 assembly, February 2009). ChIP-
on-chip was performed as described previously (26–28)
using 10 mg of either anti-MYCN, anti-histone H3
K4me3 (ab8580, Abcam), anti-histone H3 K36me3
(ab9050, Abcam), anti-histone H3 K27me3 (07-449,
Millipore), or normal mouse IgG antibody. The Human
Promoter ChIP-chip Set 244K microarray (Agilent) spans
regions roughly 5.5 kb to+2.5 kb (25 probes per gene
with a spacing of 195 nt) from the transcriptional start
sites of 17 000 human transcripts chosen as being the
best-defined by RefSeq. ChIP-on-chip data were
normalized using the limma quantile algorithm. Results
were visualized with the Integrative Genomics Viewer
v1.5.52 from the BROAD Institute (29).
Animal experiments
Animal experiments were approved by the German
Cancer Research Center institutional animal care and
use committee and the Regierungspra¨sidium Karlsruhe.
All experiments conform to the relevant regulatory stand-
ards. CB17-SCID mice were purchased from Charles
River Laboratories (Sulzfeld, Germany) and held under
standard animal care conditions in the DKFZ animal
facility. For Panobinostat studies, 1 106 BE(2)-C cells
were subcutaneously implanted into mice. Animals were
treated with 15mg/kg/d Panobinostat or solvent (5%
dextrose in water) by intraperitoneal injection 5 d/week
(30) starting 24 h after implantation (n=12 per study
group). Animals were sacrificed on day 14 of treatment,
and miR-183 expression in the xenograft was analysed by
qRT-PCR. For miR-183 overexpression studies, BE(2)-C
cells were transiently transfected with the Pre-miR
miRNA precursor for hsa-miR-183 or Negative Control
#1 (Applied Biosystems). Cells (1 106) were subcutane-
ously injected into CB17-SCID mice (n=11 per study
group) 48 h after transfection. Tumor size was measured
daily using a caliper. Tumor volume was calculated by
/6(w1w2w2), where w1 was the largest tumor
diameter and w2 was the smallest tumor diameter.
Statistical analysis
In vitro experiments included three independent replicates,
and results were compared using unpaired or paired
t-tests. In vivo effects on tumor growth by miR-183
overexpression were analysed using the non-parametric
Mann–Whitney U test (GraphPad Prism version 5.01).
For analysis of miR-183 induction by HC-toxin in
MYCN-amplified versus non-amplified cell lines in time-
course, a linear mixed model was used to evaluate the
AUC of the log-transformed measurements with a
random effect for the cell line. For statistical analysis of
miR-183 induction by HDACi at a single treatment time,
miR-183 expression was log-transformed. A mixed linear
model was used with fixed factor (MYCN-amplified/
MYCN single copy) and random intercept for each ID.
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Figure 1. pan-HDACi strongly induce miR-183 in neuroblastoma cell lines and xenografts in mice. (A) Heat map representation of miRNA profiling
(left panel) indicates significantly (P< 0.05) up- (yellow) or down-regulated (blue) miRNAs in BE(2)-C cells treated for 24 h with HC-toxin or solvent
control (methanol; MeOH). The miRNAs most strongly up-regulated are indicated together with the fold-change expression over the solvent control
and adjusted P-values (right panel). (B) Validation of strongest miR-183 induction and miR-182/miR-96 induction by HC-toxin. BE(2)-C cells were
treated as described in (A). Expression was measured by qRT-PCR and is shown relative to untreated controls (mean±SD) on a log scale. (C) HC-
toxin induced and maintained miR-183 expression over 72 h of treatment in four neuroblastoma cell lines. Expression was measured by qRT-PCR,
and is shown at several time points relative to the respective solvent-treated control cells (as mean±SD) on a log scale. miR-183 induction compared
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Statistical analysis of the number of viable and dead cells
after miR-183 overexpression compared miR-183 trans-
fectants to both negative controls. For comparison of
treatment, a mixed linear model was used with fixed
factor treatment and random intercept for each ID. For
the comparison of miR-183 expression between both
negative controls and both HDAC-specific siRNAs, a
mixed linear model was used with fixed factor treatment
and random intercept for each siRNA. For statistical
analysis of endogenous miR-183 expression levels in
cell lines, miR-183 expression was log-transformed and a
mixed linear model was used to compare MYCN-
amplified and non-amplified cell lines with random
intercept for each cell line. All mixed linear model
analyses were performed using SAS PROC MIXED,
SAS Version 9.2 (SAS Institute Inc., Cary, NC, USA).
P-values below 0.05 were considered significant.
RESULTS
miR-183 is the strongest HDACi-responsive microRNA
in neuroblastoma cells
We used miRNA array profiling to identify miRNAs
causally involved in inducing apoptosis or differentiation
or inhibiting proliferation of neuroblastoma cells after
HDACi treatment. BE(2)-C cells were treated with the
pan-HDACi, HC-toxin or solvent control for 24 h before
miRNA expression profiling. HC-toxin treatment resulted
in significant differential expression of 40 miRNAs
(Figure 1A, left panel), of which miR-183 was
most strongly up-regulated, with a 13-fold induction
(Figure 1A, right panel). MicroRNAs organized in the
same miRNA cluster, miR-182 (11.7-fold) and miR-96
(2.6-fold), were also up-regulated. Quantitative reverse-
transcriptase PCR (qRT-PCR) analysis validated miR-
183 as being the miRNA that was most dramatically
up-regulated (51.3-fold), and confirmed the 10-fold in-
duction of miR-182 and miR-96 (Figure 1B). We analysed
the kinetics of miR-183 expression after HC-toxin treat-
ment of theMYCN-amplified cell lines, BE(2)-C and Kelly
and the non-amplified cell lines, SH-SY5Y and SH-EP.
HC-toxin-induced miR-183 expression, which remained
up-regulated up to 72 h of continuous treatment, in all
four cell lines (Figure 1C). Induction of miR-183 peaked
at 80-fold in MYCN-amplified cell lines and at 10-fold in
cell lines without MYCN amplification (Figure 1C). We
next tested the influence of the clinically more advanced
pan-HDAC inhibitors, Panobinostat, PCI-24781 and
Vorinostat (31), on miR-183 expression in these four
cell lines after 24 h of continuous treatment. All three
inhibitors significantly induced miR-183 up to 95-fold
(Figure 1D and Supplementary Table S1). Similar to
HC-toxin, all three inhibitors induced stronger miR-183
up-regulation in MYCN-amplified cell lines. Collectively,
these data suggest miR-183 induction by pan-HDAC in-
hibition to be a common event in neuroblastoma cell lines
in vitro. To test the influence of HDACi treatment on
miR-183 expression in an in vivo neuroblastoma model,
BE(2)-C cells were subcutaneously injected into CB17-
SCID mice, followed by intraperitoneal injection of
Panobinostat or solvent for 5 d/week up to 14 days.
High miR-183 expression correlated with small tumor
volumes caused by Panobinostat treatment (Figure 1E).
In summary, miR-183 was strongly induced in neuroblast-
oma cells by pan-HDACi in both in vitro and in vivo
models, and cells with a MYCN amplification were more
strongly affected.
Enforced expression of miR-183 induces cell death in
neuroblastoma cells
To test the phenotypic consequences of elevated miR-183
in MYCN-amplified neuroblastoma cells, miR-183 was
transiently overexpressed in three MYCN-amplified
neuroblastoma cell lines and a MYCN-amplified neuro-
blastoma tumor sphere culture (NB8) growing under
stem cell promoting conditions. The BE(2)-C and Kelly
cell lines both carry TP53 mutations (32,33), and the
IMR-32 cell line and NB8 tumor sphere culture both
have wildtype TP53 ((33); data not shown). Transfection
efficacy was validated by assessing expression of miR-183
by qRT-PCR (Figure 2A) and of the Ezrin protein, a
known direct miR-183 target (Supplementary Figure S1;
(34)). Independent of TP53 status, enforced miR-183 ex-
pression reduced the number of viable cells up to 73%
(Figure 2B) and increased the number of trypan blue-
positive, dead cells by up to 7.5-fold compared to
negative control-transfected cells (Figure 2C). To dissect
the cell death mechanisms involved, we investigated
caspase-3-like activity in BE(2)-C and Kelly cells upon
enforced miR-183 expression, and measured a 3.9- to
5.5-fold induction of caspase-3-like activity (Figure 2D).
Flow cytometric analysis revealed a 2.5- to 2.7-fold
increase in the number of BE(2)-C and Kelly cells with
DNA fragmentation (Figure 2E). To distinguish the
extent of cell death triggered by miR-183 induction from
various other signaling cascades modulated by HDAC in-
hibitors, we transiently transfected BE(2)-C cells with an
anti-miR-183 inhibitor followed by treatment with
Panobinostat. Panobinostat treatment alone induced a
3.8-fold increase in dead cells over control, and the anti-
miR-183 inhibitor reduced this increase by 8% to 3.5-fold
Figure 1. Continued
to solvent control was significant for all cell lines (P< 0.05). Statistical analysis further compared MYCN-amplified cell lines (green-tone lines) with
cell lines having a single MYCN copy (blue-tone lines). (D) Cell lines were treated for 24 h with different clinically relevant pan-HDACi (20 nM
Panobinostat, 0.25mM PCI-24781 or 1mM Vorinostat), and miR-183 induction was measured by qRT-PCR. Expression relative to solvent-treated
controls (mean±SD) is shown on a log scale. Statistical analysis compared MYCN-amplified (green-tone bars) with single-copy (blue-tone bars) cell
lines for each pan-HDACi. (E) CB17-SCID mice carrying subcutaneous BE(2)-C cell xenografts were treated with 15mg/kg/d Panobinostat or
solvent (control) injected daily intraperitoneally for 5 d/week for 2 weeks. Significant correlation of miR-183 expression relative to solvent-treated
xenograft tumors and xenograft tumor volumes are shown from treatment day 14. Pearson’s correlation coefficient (r) and P-value are indicated.
Relative miR-183 expression in xenografts was calculated using a standard curve. *P 0.05; **P 0.001; ***P 0.0001; n.s., not significant.
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Figure 2. miR-183 induces cell death in vitro. (A) Cell lines or NB8 spheres were transiently transfected with miR-183 or negative controls (NC#1
and #2), and miR-183 expression was measured using qRT-PCR 96 h after transfection. Expression relative to mock-transfected control cultures
(mean±SD) is shown on a log scale. (B) Cell lines or NB8 spheres were transiently transfected as described in (A), and viable cells were counted
using trypan blue staining and automated cell counting. The mean±SD of viable cells (not stained with trypan blue) counted relative to the number
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(Figure 2F), indicating that HDACi treatment triggers
pro-apoptotic mechanisms, among several others,
through miR-183 induction. Together, the results demon-
strate that enforced miR-183 expression in MYCN-
amplified neuroblastoma cells induces cell death, and
that the mechanism of miR-183 induction contributes to
the cell death phenotype induced by pan-HDAC inhibi-
tors in neuroblastoma cells.
Induction of miR-183 decreases colony formation in soft
agar and inhibits neuroblastoma xenograft growth in mice
To investigate whether inducing miR-183 expression influ-
ences anchorage-independent colony formation, BE(2)-C
cells stably transfected with an inducible miR-183 con-
struct or a miR negative control expression system were
analysed in soft agar assays. Induction of miR-183
decreased colony formation to 50% (Figure 3A, lower
panels). In contrast, induction of the miR negative control
(miR-neg ctrl) in a similar range as miR-183 produced
no significant difference in colony formation upon induc-
tion (Figure 3A, upper panel). BE(2)-C cells transiently
transfected with miR-183 or negative control were
subcutaneously implanted into CB17-SCID mice and
grown as xenografts to examine potential anti-tumoral
effects of enforced miR-183 expression in vivo. Enforced
miR-183 expression inhibited neuroblastoma xenograft
growth, and resulted in 47% decrease in xenograft size
(Figure 3B). Taken together, miR-183 exerts tumor sup-
pressive functions in both a long-term in vitro assay and a
xenograft mouse model of neuroblastoma.
HDAC2 negatively regulates miR-183 expression
To narrow down the HDACs involved in miR-183 repres-
sion, we treated neuroblastoma cells with HDACi that
selectively block specific HDACs. Applying Entinostat at
a concentration that inhibits HDAC1-3 and 9 (35) caused
a 2.7- to 46.5-fold miR-183 induction in all cell lines
analysed (Figure 4A and Supplementary Table S1),
resembling the 2.9- to 50.8-fold induction by pan-
HDACi Trichostatin A (Figure 4A and Supplementary
Table S1) and by all other pan-HDACi previously
analysed (Figure 1C and D). Similarly to pan-HDACi in-
duction of miR-183, induction was stronger in the
MYCN-amplified cells. In contrast, the HDAC6-selective
inhibitor, Tubacin, and the HDAC8-selective inhibitor,
Compound 2 (36), did not induce miR-183 (Figure 4A
and Supplementary Table S1). These results suggest only
single HDACs play a role in miR-183 regulation. To
identify the HDACs causally involved, all eleven classical
HDAC family members were singly depleted in BE(2)-C
cells by siRNA-mediated knockdown using two different
siRNAs (Supplementary Tables S3 and S4). Class III
HDACs were not analysed since they are not affected by
the pan-HDACi used in our study (37). Only HDAC2
depletion induced miR-183 expression, resulting in a
10.4- to 11.4-fold induction (Figure 4B, Supplementary
Table S3 and Supplementary Figure S2A). Depletion of
HDACs 5, 7, 8 and 9 did not affect miR-183 expression
(Figure 4B). Depletion of HDACs 1, 3, 4, 6, 10 and 11
decreased miR-183 levels (Figure 4B), suggesting that
these HDAC family members may counteract the influ-
ence of HDAC2 on miR-183 expression. In line with the
induction of miR-183 by HDACi in several neuroblast-
oma cell lines (Figure 1C and D), HDAC2 depletion
induced miR-183 in three other neuroblastoma cell lines
(Figure 4C and Supplementary Figure S2B). Enforced
HDAC2 expression reduced endogenous miR-183 expres-
sion (Figure 4D and Supplementary Figure S2C) and
counteracted the siRNA-mediated induction of miR-183
by HDAC2 depletion (Figure 4E). To test if HDAC2
enforced expression counteracts in part the induction of
miR-183 by treatment with HDAC inhibitors, BE(2)-C
cells were transiently transfected with HDAC2 followed
by treatment with Entinostat. Enforced HDAC2 expres-
sion decreased the miR-183 induction triggered by
Entinostat by 30% (Figure 4F). In conclusion, our
data show that HDAC2 represses miR-183 levels.
MYCN and HDAC2 are recruited to the miR-183
promoter region
Since the strongest miR-183 induction by HDACi occurred
inMYCN-amplified cells, we assessed endogenous miR-183
expression in neuroblastoma cell lines with different
MYCN genomic backgrounds. The MYCN-amplified cell
lines, BE(2)-C and Kelly, expressed distinctly lower miR-
183 levels than SH-SY5Y and SH-EP cells, which maintain
a single MYCN copy (Figure 5A). We hypothesized that
HDAC2 and MYCN may interact to suppress miR-183
transcription, as was previously shown for the CCNG2
gene in BE(2)-C cells (38). Indeed, miR-183 levels were
higher in cells with low HDAC2 expression (Figure 5A),
supporting this hypothesis. Next, we aimed to decipher
events occurring at the miR-183 promoter region. The
miR-183 cluster is located on chromosome 7 between the
two protein-coding genes, NRF1 and UBE2H (Figure 5B).
Bioinformatic analysis predicted a putative transcription
start site (TSS) 5kb upstream of miR-183 (39). The
TSS was predicted to be 139 bp upstream of the site
described by Ozsolak and colleagues using a second
independent bioinformatic approach (40). We analysed
Figure 2. Continued
of viable cells in mock-transfected control cultures (=100%) are shown. (C) Mean numbers (±SD) of trypan blue-positive cells from cultures
described in (B) relative to mock-transfected cells (=1). (D) Cell lines were transiently transfected with miR-183 or negative control (NC#1), and
analysed for caspase-3-like activity 72 h after transfection. Mean±SD caspase-3-like activity is displayed relative to that of the negative control.
(E) Cells were stained with propidium iodide 72 h after transfection with miR-183 or negative control (NC#1). The percentage of cells in the sub-G1
phase is shown. (F) BE(2)-C cells were transiently transfected with anti-miR-183 inhibitor or anti-miR negative control (Anti-miR-NC). About 18 h
after transfection, cells were treated with 20 nM Panobinostat or solvent for 72 h. Number of dead cells were counted using trypan blue staining and
automated cell counting (mean numbers of trypan blue-positive cells relative to Anti-miR-NC-transfected and solvent-treated cells±SD). *P 0.05;
***P 0.0001.
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Figure 3. miR-183 inhibits colony formation in soft agar and suppresses neuroblastoma xenograft growth in mice. (A) The BE(2)-C cell line was
stably transfected with doxycycline-inducible expression constructs for miR-183 or a miR negative control (miR-neg ctrl). miR-183 or miR-neg ctrl
expression upon treatment with or without doxycycline (Dox) for 24 h was measured by qRT-PCR (mean±SD) (upper panel). Colony growth in
soft agar under continuous treatment with or without doxycycline (Dox) is shown for representative cultures after staining with crystal violet (lower-
left panel). The results of the soft agar assays are presented as bar graphs of the mean number of colonies (±SD) forming in doxycycline-treated
cultures relative to solvent-treated cultures (set to 100%) (lower-right panel). (B) BE(2)-C cells were transiently transfected with miR-183 or negative
control (NC#1), and subcutaneously injected into CB17-SCID mice 48 h after transfection. Xenograft tumor volumes after 8 days are presented as
box plots, and were compared using the Mann–Whitney U test. *P 0.05; **P 0.001; n.s., not significant.
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Figure 4. HDAC2 negatively regulates miR-183 expression. (A) Cell lines were treated 24 h with 1 mM Entinostat, 5mM Tubacin, 40 mM Compound
2 or 75 nM Trichostatin A, then miR-183 expression was measured using qRT-PCR. Relative expression to expression in solvent control is shown as
mean±SD on a log scale. Statistical analysis compared MYCN-amplified (green-tone bars) with MYCN-single-copy (blue-tone bars) cell lines
treated with each HDACi. (B) BE(2)-C cells were transiently transfected with 2 siRNAs (siRNA#1, #2) to specifically silence each HDAC (x-axis) or
negative control siRNAs (siNC#1, siNC#2), and miR-183 expression was analysed using qRT-PCR 96 h after transfection. Relative expression to
mock-transfected cells is presented as mean±SD, and statistics compared siRNA-transfected pairs with negative control-transfected pairs for
each HDAC. (C) Neuroblastoma cell lines were transiently transfected with siRNA#2 targeting HDAC2. Following HDAC2 knockdown
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chromatin immunoprecipitation sequencing (ChIP-Seq) ex-
periments of Kelly cell lysates using an antibody against
MYCN to determine whether MYCN is associated with
the promoter region. MYCN was significantly enriched
in a region 100–240bp upstream of the putative TSS
(Figure 5C), demonstrating an association of MYCN to
the miR-183 promoter region. Genome-wide ChIP-on-
chip assays using BE(2)-C, Kelly, SH-SY5Y and SH-EP
neuroblastoma cell lines also revealed that the epigenetic
marker for repressed chromatin, H3K27me3 (histone 3
lysine 27 tri-methylation), was enriched at the miR-183
promoter region in MYCN-amplified cell lines in compari-
son to single-copy cell lines (Figure 5D). This is in line with
the lower endogenous miR-183 expression detected in
MYCN-amplified neuroblastoma cells (Figure 5A). Marks
for activated chromatin, H3K4me3 (histone 3 lysine 4
tri-methylation), and elongation, H3K36me3 (histone 3
lysine 36 tri-methylation), were not prominently enriched
at the genomic location of the miR-183 cluster. In contrast,
both neighboring protein-coding genes, NRF1 and
UBE2H, were in a transcriptionally activated state,
characterized by both a strong enrichment for H3K4me3
and H3K36m3 and a reduced H3K27me3 association,
indicating that events at the miR-183 TSS were specific
and not a consequence of events in the surrounding
genomic area (data not shown). To confirmMYCN recruit-
ment to the miR-183 promoter region, we performed ChIP
experiments with the same anti-MYCN antibody used for
ChIP-Seq analysis. We detected a 2.8-fold enrichment for
miR-183 promoter-specific DNA with the anti-MYCN
antibody over IgG in BE(2)-C cells (Figure 5E). The
enriched region was located 430–570bp upstream of
the putative TSS, thus, validating the ChIP-Seq data
(Figure 5C). We next conducted ChIP with an antibody
against HDAC2 to assess whether HDAC2 is recruited to
the miR-183 promoter region, and detected a 2.9-fold en-
richment above IgG (Figure 5F). These results suggest that
both MYCN and HDAC2 are recruited to the miR-183
promoter region. Since HDACs 1 and 2 have been found
together as components of transcriptional repressor
complexes (15,41), we tested again by ChIP whether
HDAC1 is also recruited to the miR-183 promoter region
and found no enrichment above IgG (Figure 5F). Because
HDAC2 depletion increased miR-183 expression and
HDAC2 was recruited to the miR-183 promoter region,
we next investigated the pan-acetylation of histone H4
associated with the miR-183 promoter region. ChIP
utilizing an antibody against pan-acetyl-histone H4
revealed that HDAC2 depletion caused an increase in
histone H4 pan-acetylation associated with the miR-183
promoter region (Figure 5G). The increase in H4 pan-
acetylation indicates that epigenetic changes precede the
transcriptional activation of miR-183 expression in neuro-
blastoma cells. We performed ChIP and Re-ChIP experi-
ments to test whether MYCN and HDAC2 are recruited in
the same complexes to the miR-183 promoter region.
Chromatin precipitated in the first round of ChIP with
the HDAC2-specific antibody was subjected to a second
round of ChIP (Re-ChIP) using a MYCN-specific
antibody. Re-ChIP was compared against a Re-ChIP
using the HDAC2-specific antibody also in the second
round as a control. ChIP/Re-ChIP experiments
demonstrated a 6.8-fold enrichment for HDAC2 and a
10.8-fold enrichment for MYCN above IgG (Figure 5H).
We conclude that MYCN and HDAC2 are recruited in the
same protein complexes to the miR-183 promoter region to
suppress miR-183 transcription.
MYCN and HDAC2 are required to repress miR-183
MYCN and HDAC2 recruitment to the miR-183
promoter region suggests that both are involved in sup-
pressing miR-183 expression. We examined miR-183 regu-
lation in a neuroblastoma cell line stably transfected with
a tetracycline-inducible MYCN shRNA expression
system. shRNA-mediated MYCN knockdown decreased
MYCN expression without influencing the total HDAC2
protein level (Figure 6A). Consistent with the increase in
miR-183 expression after HDAC2 depletion (Figure 4B,
Supplementary Table S3 and Supplementary Figure S2A),
MYCN knockdown also increased miR-183 expression
(Figure 6B). ChIP experiments using these cells revealed
a reduced recruitment of HDAC2 to the miR-183
promoter region upon MYCN knockdown (Figure 6C).
To define the influence of HDAC inhibition on the
extent of MYCN recruitment to the miR-183 promoter
region, we performed anti-MYCN ChIPs followed by
miR-183 promoter-specific PCRs after Panobinostat treat-
ment of BE(2)-C cells for two different treatment periods,
2 h or 24 h. Inhibition of HDAC activity by Panobinostat
treatment for 24 h significantly reduced the recruitment of
MYCN to the miR-183 promoter site by 20%, whereas
inhibition of HDAC activity for 2 h had no major effects
(Figure 6D, upper panel). Inhibition of HDAC activity
was confirmed by the detection of increased H3 pan-
acetylation levels at both time points (Figure 6D, lower
panels). In parallel, overall MYCN expression levels upon
pan-HDAC inhibition were measured by western blot
Figure 4. Continued
(96 h post-transfection), miR-183 expression was analysed via qRT-PCR. Mean expression relative to mock-transfected cells is presented (±SD).
(D) HDAC2 expression was enforced in BE(2)-C cells via transient transfection with a HDAC2 expression construct, and miR-183 expression was
analysed by qRT-PCR 72 h after transfection. Mean expression relative to empty vector-transfected cells±SD is shown. (E) Enforced HDAC2
expression counteracted induction of miR-183 by HDAC2 knockdown. BE(2)-C cells were transiently transfected with siRNA#2 against HDAC2,
and 24 h later with the HDAC2 expression construct. Cells were harvested 120 h after siRNA and 96 h after plasmid transfection and qRT-PCR
performed for miR-183 expression (mean expression relative to empty vector- and mock-transfected cells±SD). Western blot for HDAC2 expression
72 h after siRNA and 48 h after plasmid transfection with the ß-actin loading control are shown below. (F) Enforced HDAC2 expression counter-
acted miR-183 induction upon HDACi treatment. BE(2)-C cells were transiently transfected with the HDAC2 expression construct followed by
treatment with 1 mM Entinostat or solvent control. RNA was extracted 72 h after transfection and 24 h after HDACi treatment and qRT-PCR
performed for miR-183 expression (mean expression relative to empty vector- and solvent-treated cells±SD). Western blot for His-tagged HDAC2
using an anti-Penta-His antibody with the ß-actin loading control are shown below. *P 0.05; **P 0.001; ***P 0.0001; n.s., not significant.
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Figure 5. MYCN and HDAC2 are recruited to the miR-183 promoter region in the same complexes. (A) qRT-PCR analysis of endogenous miR-183
expression levels in neuroblastoma cell lines. Western blots for HDAC2 and MYCN expression with the GAPDH loading control are shown below
each cell line. Statistical analysis compared cell lines with (green-tone bars) and without (blue-tone bars) MYCN amplifications. (B) Schematic
representation of genomic localization and organization of the miR-183 cluster (based on the UCSC genome browser, GRCh37/hg19 assembly,
February 2009) with distances to neighboring protein-coding genes. TSS, region of predicted putative transcription start site; arrows, direction of
transcription. (C) ChIP-Seq analysis from Kelly cell lysates using an antibody detecting MYCN showing MYCN association in the promoter region
of miR-183 cluster (black bars) superimposed on the miR-183 cluster genomic organization. (D) Enrichment of H3K27 tri-methylation at the miR-
183 promoter region in MYCN-amplified cell lines. Heat map representing ChIP-on-chip data for the H3K4me3, H3K27me3 and H3K36me3
epigenetic marks at the miR-183 cluster in neuroblastoma cell lines superimposed on the genomic probe localization. Enrichment was calculated
as the log2 ratio of antibody (ab) to control, and is shown as graded color bars ranging from no binding (blue) to strong binding (red). (E, F) ChIP
analysis in BE(2)-C cell lysates showing MYCN (E) and HDAC2 (F) recruitment to the miR-183 promoter region and no recruitment of HDAC1
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analysis. While Panobinostat treatment for 2 h had no
major effects on MYCN protein levels, treatment for
24 h strongly reduced MYCN protein levels (Figure 6D,
lower panels). In conclusion, at early time points (2 h)
HDAC inhibition did not change recruitment of MYCN
to the miR-183 promoter region. It remains to be
elucidated whether the reduced recruitment of MYCN to
the miR-183 promoter site at 24 h of Panobinostat treat-
ment is caused by the longer inhibition of HDAC activity
compared to the 2 h time point, by the reduction in overall
MYCN expression or by both mechanisms. Taken
together, these data demonstrate that MYCN and
HDAC2 are both required for the suppression of miR-
183 expression in neuroblastoma cells (model in Figure 7).
DISCUSSION
Here we identified miR-183 as the strongest pan-HDACi-
responsive miRNA in highly malignant MYCN-amplified
neuroblastoma cells, and unraveled the distinct tumor
suppressive properties of miR-183 in this childhood ma-
lignancy. A review of the literature indicates that miR-183
expression is dysregulated in different human cancer
entities. It has been described that miR-183 is up-regulated
in colorectal cancer (42,43), prostate cancer (44) and
hepatocellular carcinomas (45) compared to matched
adjacent normal tissues. In contrast, miR-183 expression
has been found to be down-regulated in ovarian cancer
(46), breast cancer stem cells (47) and osteosarcomas (48)
compared to control cells/tissues. Beyond these expression
studies, miR-183 was identified in functional studies as a
potential inhibitor of metastatic invasion in both lung
cancer and osteosarcoma cell lines (34,48). These
findings suggest that miR-183 can act as an oncogene or
a tumor suppressor, depending on the cellular context.
In the literature, several direct targets of miR-183 are
described. For example, integrin beta 1 (ITGB1) is
targeted by miR-183 in HeLa cells (49), and it has been
shown in a previous study, that an antisense oligonucleo-
tide to ITGB1 or an antibody against ITGB1 blocking
integrin-mediated cell adhesion induces apoptosis in
neuroblastoma cells (50). Another reported miR-183
target is the polycomb group family member BMI-1 in
pancreatic cancer cell lines (51). BMI-1 is highly expressed
in neuroblastoma cell lines and primary tumor samples
(52), has been shown to inhibit the apoptotic activity of
MYCN in neuroblastoma cells, and siRNA-mediated
down-regulation of BMI-1 resulted in decreased colony
growth in soft agar assays and impaired xenograft
growth in mice (52). Thus, down-regulation of ITGB1
and BMI-1 expression by miR-183 could potentially con-
tribute to the induction of cell death, decrease in colony
formation in soft agar and inhibition of neuroblastoma
xenograft growth mediated by miR-183 enforced expres-
sion. Furthermore, isocitrate dehydrogenase 2 (IDH2) was
recently identified as a direct miR-183 target in glioma
cells (53) and it has been reported that overexpression of
IDH2 resulted in increased resistance to staurosporine-
induced oxidative stress by inhibition of mitochondrial
production of reactive oxygen species (ROS) after cyto-
chrome c release in neuroblastoma cells (54). Beyond these
targets, it has been described that miR-183 directly regu-
lates Ezrin in lung and osteosarcoma cell lines (34,48), and
our data indicate that miR-183 down-regulates Ezrin ex-
pression also in neuroblastoma cells. It remains to be
elucidated whether the potential regulation of all those
proteins by miR-183 in neuroblastoma cells contributes
to the phenotype described in our study.
Identification of actions consistent with a tumor sup-
pressive function of high miR-183 expression levels in dif-
ferent preclinical neuroblastoma models prompted us to
decipher the transcriptional regulation of miR-183, which
can be distinctly induced by diverse small molecule pan-
HDACi independent of their chemical structure. We con-
ducted a RNAi-mediated screen of the 11 classical
HDACs categorized into classes I, IIa, IIb and IV, and
found that only HDAC2 depletion caused an increase in
miR-183 expression. This could be mimicked by treating a
panel of neuroblastoma cell lines with small molecules in-
hibiting HDAC2 enzymatic activity. In contrast, HDAC6-
and HDAC8-specific small molecule inhibitors did not
induce miR-183 expression, supporting the results of our
RNAi screen. HDAC2 depletion increased histone H4
pan-acetylation associated with the miR-183 promoter
region, indicating increased transcriptional activation.
Furthermore, our RNAi-mediated HDAC screen showed
an opposing effect of class I HDACs, 1 and 3, compared
to HDAC2 on miR-183 expression. Both HDAC1 and
HDAC3 depletion triggered miR-183 repression,
indicating non-redundant functions of class I HDAC
family members in neuroblastoma. This also applies for
the fourth HDAC I family member, HDAC8. We have
previously shown that targeting of HDAC8 in neuroblast-
oma cells by small molecule inhibitors or RNAi inhibits
proliferation and induces differentiation (55). However,
neither selective small molecule inhibition of HDAC8
nor HDAC8 depletion affected miR-183 expression,
indicating that miR-183 is not targeted by HDAC8,
neither directly nor indirectly, in neuroblastoma cells.
In line with these findings, the phenotype caused by
enforced miR-183 expression clearly mimicked the
HDAC2-depletion phenotype, namely, both induced
apoptosis, but not the HDAC8-depletion phenotype,
which was characterized by the initiation of differentiation
Figure 5. Continued
(F). Bars represent mean relative enrichment above the IgG control (±SD), detected by qRT-PCR of the miR-183 promoter region. (G) ChIP
showing increased histone H4 acetylation at the miR-183 promoter region after HDAC2 knockdown. BE(2)-C cells were transiently transfected with
siRNA against HDAC2 (siRNA#2) or negative control (siNC#1), and ChIP analysis with a pan-acetyl-histone H4 antibody was performed 96 h after
transfection. Bars show mean fold enrichment above siNC#1 control (±SD) measured by miR-183 promoter region qRT-PCR. (H) Re-ChIP
showing recruitment of MYCN and HDAC2 in the same complexes. First ChIP conducted on BE(2)-C cell lysates with an anti-HDAC2
antibody. Chromatin precipitates used in the second ChIP with the indicated antibodies (x-axis). Bars represent mean enrichment above the
Re-ChIP IgG control (±SD) detected by qRT-PCR of the miR-183 promoter region. *P 0.05; **P 0.001; n.s., not significant.
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(55). In addition to the class I HDACs, HDAC4 (class
IIa), HDACs 6 and 10 (class IIb) as well as the sole
class IV family member, HDAC11, were shown to either
directly or indirectly influence miR-183 expression in the
opposite direction to HDAC2. Together, these data
indicate that the strong and permanent induction of
miR-183 by pan-HDACi treatment is caused by the en-
zymatic blockage of HDAC2, and that HDAC2 blockage
overrides the miR-183 repression triggered by the inhib-
ition of the other HDACs. Further, we demonstrate that
Figure 6. miR-183 repression requires MYCN and HDAC2. (A) MYCN and HDAC2 expression in the IMR-32 cell line, harboring a tetracycline-
inducible MYCN shRNA expression construct, is shown after 48 h of treatment with or without tetracycline (Tet). ß-actin served as a loading
control. (B) miR-183 expression was analysed by qRT-PCR in the same neuroblastoma cell model after MYCN shRNA induction. Bars show mean
miR-183 expression relative to solvent-treated cells±SD. (C) ChIP analysis with a HDAC2-specific antibody revealed less HDAC2 recruitment (gray
bar) to the miR-183 promoter region in lysates of cells treated as in (A) after MYCN depletion. Mean enrichment detected by miR-183 promoter
qRT-PCR relative to solvent-treated cells (±SD) is shown. (D) ChIP analysis investigating MYCN recruitment to the miR-183 promoter region
upon Panobinostat treatment. BE(2)-C cells were treated with Panobinostat or solvent for 2 h or 24 h. Bars represent mean MYCN recruitment to the
miR-183 promoter region (±SD) relative to solvent-treated cells at each time point (=100%) measured by miR-183 promoter region qRT-PCR.
Western blot for MYCN expression and histone H3 pan-acetylation with the H3 and ß-actin loading controls are shown below. *P 0.05; n.s., not
significant.
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MYCN is an important player in recruiting HDAC2 to
the miR-183 promoter region. Previous studies in neuro-
blastoma cells have shown that MYCN recruits HDACs
to promoter sites of target genes to silence their expres-
sion. A co-recruitment of HDAC2 and MYCN to the
CCNG2 gene promoter has been described, and siRNA-
mediated HDAC2 or MYCN knockdown or HDACi
treatment reversed CCNG2 transcriptional repression
(38), in line with our results for miR-183. A MYCN
autoregulatory circuit has also been shown to involve re-
cruitment of HDAC2 to theMYCN promoter region (56).
These findings suggest that recruiting HDAC2 may be a
common mechanism by which MYCN exerts its oncogenic
properties in neuroblastoma cells. A similar regulatory
mechanism exerted by MYCN has been shown for
another HDAC as well. MYCN has been reported to
recruit HDAC1 to the TG2, TRKA and p75NTR pro-
moters in neuroblastoma cells (57,58).
Treatment with pan-HDACi not only blocks HDAC2
activity but also reduces MYCN protein levels (19),
thereby decreasing HDAC2 recruitment to the miR-183
promoter and resulting in an additive induction of
miR-183. Total induction is significantly higher in
MYCN-amplified cell lines than in cell lines without
MYCN amplifications, reflecting the inverse endogenous
expression levels of MYCN and miR-183 and the tran-
scriptional suppression mediated by HDAC2 and
MYCN co-recruitment.
The quantitative discrepancies in miR-183 induction
observed between HDAC inhibition by drugs and
HDAC2 or MYCN knockdown are most likely due to
the dual effects of HDAC inhibitors in neuroblastoma
cells on both, HDAC activity and overall MYCN expres-
sion levels. They simultaneously inhibit the enzymatic
activity of HDAC2 and suppress MYCN expression
levels and thereby trigger miR-183 expression in parallel
via the different regulatory mechanisms unravelled in this
study. The HDAC2 and MYCN knockdown studies spe-
cifically target the individual protein levels without imme-
diately affecting other regulatory mechanisms, although
secondary effects, e.g. the reduced recruitment of
HDAC2 to the miR-183 promoter site upon MYCN
knockdown occur over time. Taken together, the quanti-
tative discrepancies in miR-183 induction between small
molecule HDAC inhibitors and HDAC2 or MYCN
knockdown are most likely due to the broader spectrum
of changes triggered by HDAC inhibitor treatment.
This study identifies miR-183 as a tumor suppressive
miRNA in neuroblastoma cells, and unravels its transcrip-
tional regulation by HDAC2 and MYCN. The under-
standing of the molecular mechanisms of this regulation
supports the further development of targeted therapeutic
intervention based upon HDAC inhibition in neuroblast-
oma patients, especially those with MYCN-amplified
tumors. This approach would re-activate miR-183 ex-
pression in the tumor, triggering the cell intrinsic tumor
suppressive properties.
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Figure 7. Schematic model of MYCN/HDAC2-mediated miR-183 repression in neuroblastoma. (A) MYCN and HDAC2 are recruited in the same
complexes to the miR-183 promoter region and repress miR-183 expression. The repressive epigenetic mark, tri-methylation of H3K27, is more
enriched in neuroblastoma cells harboring MYCN amplifications, and miR-183 expression is lower. (B) HDAC2 causes transcriptional repression of
miR-183. HDAC2 inhibition or depletion results in miR-183 induction. Increased histone H4 pan-acetylation in the miR-183 promoter region in
response to HDAC2 knockdown indicates epigenetic changes and transcriptional activation of miR-183. (C) MYCN is important for HDAC2
recruitment to the miR-183 promoter region, since MYCN depletion reduces HDAC2 recruitment to the promoter and increases miR-183 expression.
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